GERM-02. NOVEL TREATMENT APPROACH FOR PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) PURE EMBRYONAL CARCINOMA WITH INTENSIVE INDUCTION AND CONSOLIDATION MARROW-ABLATIVE CHEMOTHERAPY FOLLOWED BY AN ANTI-CD30 ANTIBODY-DRUG CONJUGATE WITHOUT IRRADIATION

摘要

BACKGROUNDPrimary CNS embryonal carcinoma confers a poor prognosis despite conventional chemotherapy and radiotherapy. We report upon a novel treatment approach to CNS embryonal carcinoma using intensive, including marrow-ablative, chemotherapy followed by maintenance therapy with brentuximab-vedotin without irradiation. Brentuximab-vedotin is an anti-CD30 antibody conjugated to an anti-tubulin synthetic analog.